Eli Lilly Gets Green Light To Sell Weight-Loss Drug in China

Eli Lilly and Co. (LLY) announced connected its WeChat relationship Friday that it has won support from Chinese regulators to waste tirzepatide for weight nonaccomplishment successful nan country.

Tirzepatide is nan progressive constituent successful Lilly’s injectable glucosuria supplier Mounjaro and weight-loss supplier Zepbound. Mounjaro antecedently was approved successful China for glucosuria treatment.

The support comes aft Danish rival Novo Nordisk (NVO) announced successful June that its weight-loss supplier Wegovy received akin support successful China. Last week, a JAMA Internal Medicine study recovered that tirzepatide caused greater weight nonaccomplishment than semaglutide, nan progressive constituent successful Novo Nordisk's Ozempic and Wegovy.

Fierce Competition Between Eli Lilly, Novo Nordisk successful Weight-Loss Market

Competition betwixt nan drugmakers successful nan world’s second-largest system will beryllium crucial, pinch nan world weight-loss marketplace expected to scope $77 cardinal annually by 2030, according Morgan Stanley analysts. 

Eli Lilly did not specify erstwhile income of nan supplier would statesman successful China, aliases really galore doses would beryllium sold, according to Reuters. The drugmaker did not instantly respond to Investopedia's petition for comment.

Eli Lilly shares roseate 1.4% to $860.50 arsenic of 1 p.m. ET Friday and are up almost 50% year-to-date. Novo Nordisk American depositary receipts (ADRs) were up 1.7% to $132.19 and person added astir 28% successful 2024.